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Catheter Ablation of Atrial Fibrillation
The Search for Substrate-Driven End Points
Demosthenes Katritsis, MD, PHD,* Faisal M. Merchant, MD,† Theofanie Mela, MD,‡
Jagmeet P. Singh, MD, PHD,‡ E. Kevin Heist, MD, PHD,‡ Antonis A. Armoundas, PHD§
Athens, Greece; and Boston and Charlestown, Massachusetts
Indications for catheter ablation of atrial fibrillation (AF) have expanded to include increasingly complex cases,
such as long-standing persistent AF and structural heart disease. Although pulmonary vein isolation remains es-
sential for most ablation procedures, the role of substrate modification has taken on increasing importance. De-
spite the various ablation strategies available, single-procedure efficacy remains suboptimal among patients
with structural heart disease or long-standing persistent AF, where recurrence rates may exceed 50% after a
single procedure. These high rates of AF recurrence support the notion that currently available procedural end
points are ineffective in identifying which patients are most likely to benefit from substrate modification and
defining when that substrate has been sufficiently modified such that additional ablation is unnecessary. In or-
der to improve outcomes, the next generation of procedural end points should seek to define specific properties
of the underlying atrial electrical substrate and characterize the impact of catheter ablation on those electro-
physiologic properties. The use of substrate-driven end points would be a major step in the process of moving
from empiric ablation lesions to a customized ablation strategy based on atrial physiology. In this article, we
review current approaches to catheter ablation of AF and discuss specific procedural end points as they pertain
to each ablation strategy. We also provide a paradigm for the future development of novel substrate-driven pro-
cedural end points. (J Am Coll Cardiol 2010;55:2293–8) © 2010 by the American College of Cardiology
Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.03.016a
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datheter ablation is an established therapeutic option for
ertain patients with atrial fibrillation (AF). The highest
rocedural success rates after catheter ablation are typically
een in patients with paroxysmal AF and minimal structural
eart disease (1). Recent data also support the use of
atheter ablation in clinical settings previously deemed
nsuitable, such as long-standing persistent AF (2) and left
entricular dysfunction (3).
Although the specific mechanisms that give rise to AF
ave not been completely elucidated, a paradigm of triggers
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010, accepted March 1, 2010.nd substrate has emerged. According to this model, when
igh-frequency discharges from focal triggers encounter a
ufficiently heterogeneous atrial substrate, they give rise to
brillatory conduction, which manifests clinically as AF.
lthough the relative importance of triggers and substrate
ay vary from patient to patient, considerable experimental
4,5) and clinical (6) evidence suggests that as AF progresses
rom paroxysmal to persistent, the atrial substrate becomes
ncreasingly abnormal and may play a relatively more
mportant role in maintaining the arrhythmia.
Building on this paradigm, current catheter ablation
trategies fall into 2 broad categories: ablation or isolation of
ocal triggers to prevent AF initiation and atrial substrate
odification to impede AF perpetuation. With these ap-
roaches, single-procedure success rates (variably defined)
re approximately 60% to 80% for patients with paroxysmal
F, with 30% to 40% of patients requiring a second
rocedure to achieve long-term freedom from AF (7).
hese success rates suggest that the most widely used
rocedural end points to document complete electrical
solation of the pulmonary veins (PVs) during ablation of
aroxysmal AF are reasonably effective in defining a proce-
ural end point for most patients. Even among patients who
o experience clinical AF recurrence, the dominant mech-
nism of recurrence in most cases seems to be reconnection
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Procedural End Points for AF Ablation May 25, 2010:2293–8of the PVs (8,9), suggesting that
the ability to create more perma-
nent ablation lesions may also
provide an important opportu-
nity to improve outcomes (10).
This review focuses on the role of
novel procedural end points as a
means to improving outcomes,
but the importance of enhanced
energy delivery systems to create
more permanent lesions cannot
be overlooked.
Although many patients with late recurrence after parox-
smal AF ablation have reconnected PVs, a smaller percent-
ge of patients undergoing repeat procedures for AF recur-
ence are found to have non-PV foci that may not have been
dentified or targeted during the initial procedure. Estimates
ary, and 4% to 42% of patients having repeat ablation
rocedures for paroxysmal AF need ablation of non-PV foci
uring the follow-up procedure (9,11,12). In these patients,
he role of non-PV triggers and atrial substrate may play a
ore important role in maintaining AF. The use of novel
rocedural end points may provide an opportunity to
dentify these patients and perform additional, non-PV–
argeted ablation during the index procedure.
Moving from paroxysmal to persistent AF, the goal of
dentifying robust substrate-driven procedural end points
akes on even greater importance. Although complete iso-
ation of the PVs is recommended as the cornerstone of
ost ablation procedures, there is widespread recognition
hat among patients with long-standing persistent AF, PV
solation alone may be insufficient (1,13). The efficacy of AF
blation is related to the extent of ablated tissue (14,15), and
ecause ablation is being performed in increasingly complex
atients, there has been a trend toward more extensive
esions performed in a stepwise manner (16,17). However,
oncerns have also been raised that more extensive ablation
ay increase the risk of complications (18) and impair left
trial mechanical properties (19,20).
The importance of robust procedural end points stems
rom the need to balance efficacy and safety. Current data
uggest that both the efficacy of ablation and the risk of
omplications may be related to the extent of tissue ablated.
urrently available procedural end points have largely fo-
used on documenting the completeness of a particular
blation lesion set or on slowing the AF cycle length and
erminating the arrhythmia. However, these end points
rovide limited information about the long-term pro-
brillatory potential of the atrium and cannot necessarily be
sed to guide decisions regarding the risks and benefits of
dditional ablation. Therefore, the development of new end
oints that can be applied in real time to determine when
nough ablation has been performed to sufficiently modify
he atrial substrate may be critical to improving safety and
Abbreviations
and Acronyms
AF  atrial fibrillation
CFAE  complex
fractionated atrial
electrogram
DF  dominant frequency
HFS  high-frequency
stimulation
PV  pulmonary veinfficacy.In this paper, we will briefly discuss the pathophysiologic
asis for various AF catheter ablation techniques and review
he currently available procedural end points for each
blation strategy. We conclude with a discussion about
uture directions in the search for new substrate-driven
rocedural end points.
blation Targeting PV Foci
uilding on the seminal observations of Haissaguerre et al.
21), a number of groups have reported high success rates
or paroxysmal AF treated with catheter ablation to isolate
V foci (Fig. 1) (22–28). These studies have demonstrated
he presence of tissues capable of generating spontaneous
lectrical activity within the muscular sleeves that extend
round the PVs and that focal discharges from these sites
re capable of initiating AF. As outlined in the recent
onsensus statement on AF ablation (1), isolation of the
Vs remains the backbone of most AF catheter ablation
rocedures, and therefore the use of procedural end points
o define the completeness of isolation is an important step
n achieving a high success rate.
However, end points to confirm the adequacy of PV
solation vary. Both entrance block with the use of a circular
apping catheter with tightly spaced electrodes (29) and
xit block by pacing within the PVs (30) have been
dvocated as end points. But even with the use of both
ntrance and exit block, early PV reconnection can be seen.
s such, employing a waiting period of 30 to 40 min after
blation followed by repeat assessment of block has been
dvocated as an adjunctive end point (30), although later
lectrical reconnection of PVs is frequently seen and can be,
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Figure 1 Success Rates of PV-Targeted
Catheter Ablation of Paroxysmal AF
Mean duration of follow-up (days [d]) listed above each study.
AF  atrial fibrillation; PV  pulmonary vein.
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May 25, 2010:2293–8 Procedural End Points for AF Ablationlthough not necessarily (31), a source of AF recurrence.
ast, local electrogram voltage abatement during RF appli-
ation has also been used to document adequate PV isola-
ion (32).
In addition to isolating triggers, the use of PV targeted
blations, especially antral and circumferential PV lesions,
ay also play a substrate-modifying role by eliminating
nisotropic conduction properties at the PV-left atrial junc-
ion (33). By modifying conduction in this region, ablation
t the PV-left atrial junction may hinder re-entry and
erpetuation of AF (33). Additionally, PV targeted ablation
as a significant impact on other markers of left atrial
ubstrate, including dominant frequency gradient (34), frac-
ionated electrogram distribution (35), and autonomic func-
ion (36). However, the effect of PV-targeted ablation on
ltering the atrial substrate remains poorly defined because
urrently available procedural end points are largely unable
o distinguish between the trigger-isolating and substrate-
odifying benefits of these various PV-targeted techniques.
Additionally, several studies have looked at the efficacy
f empiric isolation of all pulmonary veins versus identi-
cation and selective isolation of arrhythmogenic veins
37,38). These studies have demonstrated shorter proce-
ure times, less application of radiofrequency energy, and
omparable efficacy with selective vein isolation. How-
ver, techniques for identifying arrhythmogenic veins
ary substantially, and until this approach is more broadly
alidated, empiric isolation of all veins remains the most
idely used technique.
inear Lesions
n an attempt to recapitulate the early success of surgically
laced linear ablation lesions, a number of catheter-based
inear lesions have been advocated to improve long-term
uccess rates. Linear lesions along the roof of the left atrium
onnecting the superior aspects of the left and right upper
V isolation lesions (“roof” line) and linear lesions along the
egion between the mitral annulus and the left inferior PV
mitral isthmus) may improve clinical outcomes (18,39,40).
In contemporary practice, much of the emphasis on
erforming linear lesions has focused on preventing post-
blation atypical atrial flutters. But beyond the prevention of
ost-ablation atrial tachyarrhythmias, linear lesions may
lso play a salutary role in modifying substrate and prevent-
ng AF recurrence (41,42). Although complete linear lesions
ay not be necessary for substrate modification (41), in-
omplete linear lesions may have a proarrhythmic effect
43). A number of procedural end points have been used to
ocument bidirectional block around linear ablation lesions,
ncluding demonstration of a corridor of double potentials
long the length of the ablation line during pacing and
emonstration of an activation detour when pacing from
ither side of the line (18,40). rlectrogram-Guided Ablation
nisotropic re-entry leading to rotors with high dominant
requency (44) has been proposed as a potential mechanism
or the genesis of AF. Elimination of these rotors and AF
ests may be 1 of the mechanisms by which real-time
requency analysis or complex fractionated atrial electro-
ram (CFAE)-guided ablation prevents AF (45,46). A
umber of groups have reported high success rates with
ailored approaches that target drivers of AF through
pectral analysis and electrogram-guided ablation during AF
r sinus rhythm (16,46,47). Studies have suggested that a
reponderance of CFAE sites exist in close proximity to the
Vs (48) or sites of autonomic ganglionated plexi (49) and,
herefore, substantial overlap may exist between CFAE-
argeted lesion sets and other ablation strategies. Therefore,
he relative merits of these ablation strategies and the
pportunities for synergy between them remain to be
efined.
Procedural end points for electrogram-guided ablation
ave included slowing of fractionated activity (50) or com-
lete elimination of all complex fractionated activity (46).
ther frequently used end points during electrogram-
uided ablation include acute termination for patients with
ersistent AF and noninducibility for patients with parox-
smal AF. One of the most important questions regarding
lectrogram-guided ablation is whether all sites of complex
ractionated activity need to be identified and isolated or
hether certain electrophysiologic characteristics can be
sed to identify critical sites (45,50). Although the use of
FAE-guided ablation end points is still a work in progress,
t represents a step forward in the quest to identify proce-
ural markers that are reflective of the underlying atrial
lectrophysiologic substrate.
utonomic Denervation
reas rich in autonomic innervation may be a source of
ctivity that triggers AF (51). High-frequency stimulation
HFS) around the PV-left atrial junction may identify
anglionated plexi, which serve as a source of vagal reflexes
apable of inducing and perpetuating AF through spatial
eterogeneity of refractoriness (52). Damage to ganglion-
ted plexi, usually located 1 to 2 cm outside of the PV ostia,
as been proposed as an effect of antral PV ablation (53).
Vagal reflexes, including bradycardia, asystole, atrioventric-
lar block, or hypotension, may be elicited by HFS in the
egion of the autonomic ganglia. As a procedural end point,
F is applied in these regions until vagal reflexes are no longer
licited (52,53). However, in certain circumstances, vagal
eflexes may not be elicited during application of RF energy,
nd specific ablation of autonomic ganglia identified by HFS is
ot necessarily more effective than an anatomic approach to
utonomic denervation (54). Additionally, in cases where
FS is used, the importance of abolishing all sites of vagaleflex and the potential role of autonomic ganglia in other
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Procedural End Points for AF Ablation May 25, 2010:2293–8ites (i.e., right atrium) have not been clarified. Because
oth sympathetic and parasympathetic elements reside in all
ajor left atrial ganglionated plexi (55), denervation lesions
ay also unavoidably affect both components of the auto-
omic nervous system. Thus the impact of regional ablation
n the components of the autonomic system cannot be
asily deduced, and the clinical relevance of these observa-
ions for guiding autonomic denervation-based ablation
trategies remains unclear.
ombined Approaches
n most patients, multiple mechanisms likely contribute to
he initiation and perpetuation of AF. Therefore, tailored
pproaches combining more than 1 ablation technique have
een described. Using combined approaches, the extent of
eft atrial ablation has been advocated as a marker of
ong-term success and as an adjunctive procedural end point
15). Pappone et al. (14) have suggested that a greater extent
f left atrial ablation (average 30%) is associated with
mproved outcomes in both paroxysmal and persistent AF.
his metric is based on the idea that more extensive
blation-induced damage is associated with a higher prob-
bility of modifying the atrial substrate sufficiently to pre-
ent AF. However, given concerns that increased areas of
car with low voltage and slowed conduction in the left
trium may be proarrhythmic (56), it is unlikely that extent
f ablation will evolve into an adequate procedural end
oint.
Acute termination of AF or slowing of the fibrillatory
ycle length has also been used as a procedural end point in
umerous studies (24,45,57) and has been associated with
ong-term freedom from AF (58). Additionally, AF induc-
bility after ablation has been studied prospectively as a
rocedural end point and as a marker to guide the need for
urther ablation. A number of stepwise or tailored ap-
roaches have implemented increasing ablation lesions until
F is rendered noninducible, by rapid atrial pacing and/or
nfusion of isoproterenol. Several studies (24,39,59) have
uggested that noninducibility can be used as a procedural
nd point with improved short- to midterm outcomes
ompared with ablation procedures in which inducibility
as not specifically targeted. However, in cases of long-
tanding persistent AF, many operators do not attempt to
nduce AF at the end of the procedure, thereby limiting the
tility of this technique.
ovel Procedural End Points
nd Emerging Opportunities
aroxysmal AF. Given the established role of PV triggers
n paroxysmal AF, the development of new substrate-driven
rocedural end points may have a limited role in guiding
blation therapy. However, a number of reports have dem-
nstrated important changes in the atrial substrate of
atients with paroxysmal AF, including alterations in pat-
erns of dominant frequency (60), conduction velocities/ fefractoriness, and sinus node dysfunction (61). Tools to
dentify these early changes may allow implementation of
pstream therapies capable of preventing the progression
rom paroxysmal to persistent AF. Although the specific
ole of these substrate-driven markers for guiding catheter
blation of paroxysmal AF remains to be determined, these
arly insights suggest that substrate could play an increas-
ngly prominent role in treating patients along the spectrum
rom paroxysmal to persistent.
ersistent AF. The real promise for new substrate-driven
arkers lies in their role as procedural end points for
blation of long-standing persistent AF. Despite the in-
reasingly complex list of AF catheter ablation strategies,
ost currently available procedural end points are designed
rimarily to document the completeness of a particular
esion set. Few, if any, end points are capable of defining the
verall impact of ablation on the propensity of an individual
atient to develop recurrent AF. In some ways, the search
or procedural end points has failed to keep pace with
dvances in other aspects of AF ablation technology.
It would be highly beneficial if the next generation of
rocedural end points was capable of gauging the profibril-
atory potential of the atrium as a whole, rather than serving
nly to document the completeness of a particular lesion set.
n this manner, new end points could be used to define
hen the arrhythmogenic potential of the underlying PVs
nd atrium has been sufficiently modified to prevent AF
ecurrence. As such, future research efforts should seek to
dentify electrophysiologic markers with certain specific
haracteristics that would allow them to serve as useful
rocedural end points, such as:
• The ability to measure the profibrillatory potential of
the PVs and atrium in real time
• A means to gauge the impact of ablation on the
underlying substrate, regardless of the specific ablation
strategy or lesion set being used
• A clinically-validated threshold of change in the elec-
trophysiologic marker that, if achieved during the
course of ablation, would suggest that the arrhythmo-
genicity of the atrium has been sufficiently modified
such that further ablation would be unnecessary and
potentially harmful
• A metric to predict clinical outcome and freedom from
AF recurrence
Identifying a single validated electrophysiologic marker to
erve all of these purposes may be impractical. However, it
s conceivable that a panel of electrophysiologic markers
ay be capable of meeting these needs.
A number of electrophysiologic markers have already
een investigated as tools to measure properties of the
lectrical substrate during ablation. Many of these markers
re able to provide information about the underlying atrial
ubstrate without regard to the specific ablation strategy
eing used. For example, spectral analysis and dominant
requency (DF) mapping has been studied extensively as it
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May 25, 2010:2293–8 Procedural End Points for AF Ablationertains to the effects of catheter ablation on the underlying
ubstrate, and a number of studies have demonstrated
eductions in DF after ablation at various sites (34,47,62).
dditionally, at least 1 report has demonstrated that the
linical efficacy of electrogram-guided ablation in persistent
F may be associated with the degree of abatement in DF
62). Another preliminary report suggested that among
atients undergoing ablation of persistent AF, a decrease in
F of 11.5% during ablation was associated with signif-
cantly better outcome than those who failed to achieve this
hreshold. Patients achieving this threshold had similar
utcomes to those who achieved acute termination of AF
uring ablation, but with significantly shorter procedure
imes (63). If confirmed prospectively, observations such as
hese provide proof of concept that markers of the atrial
ubstrate can be used in real time to guide ablation therapy.
As discussed above, CFAE-guided ablation also repre-
ents a significant advance in the use of substrate-driven
arkers. However, CFAE identification is highly depen-
ent on operator judgment, making it difficult to develop
uantitative metrics that can be used to define procedural
nd points. Recent reports looking at automated CFAE
etection and mapping algorithms (64) may serve as a step
oward quantification of CFAE-guided ablation. In this
ontext, future studies may seek to determine whether
pecific thresholds such as percent or absolute reduction in
FAE sites can be identified, which would predict freedom
rom AF recurrence.
Prospective studies will be crucial in determining whether
hese or other substrate-driven markers are capable of
efining an end point for ablation with a high level of safety
nd efficacy. Extension of these observations and identifi-
ation of other novel markers of atrial arrhythmogenic
ubstrate holds substantial promise for improving outcomes
f AF catheter ablation. As such, the search for substrate-
riven procedural end points represents a major step in the
ovement away from empiric ablation sets and toward truly
ustomized ablation based on atrial electrophysiology.
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